 
         
         
         Abstract
         
         The first objective of this study was to examine the intermediary metabolism of plasma
            amino acids and keto acids in streptozotocin (STZ)-treated rats. Plasma α-aminobutyrate
            (α-ABA) concentration in STZ rats was 1.5-fold greater than in control (CNT) animals
            at 1 month. In contrast, the level of plasma α-ketobutyrate (KB), which is transaminated
            to α-ABA, did not differ significantly between STZ and CNTs at 1 month, and also increased
            with age. Additionally, HPLC analysis revealed consistent profiles containing peaks
            of unknown origin. Two pathways exist for the formation of α-KB, either from the action
            of threonine dehydratase or via homocysteine, the latter metabolite being closely
            associated with the development of cardiovascular disease. These observations suggest
            that uncharacterized metabolites, including plasma α-KB, may be potential risk factors
            for the development of diabetic complications. We carried out preparatory experiments
            on non-diabetic rats to investigate the influence of α-KB and confirmed this metabolite
            had no adverse effects. The second aim of the study was to compare vascular wall thickness
            in diabetic rats treated or untreated with α-KB with CNT animals in order to determine
            the effects of α-KB on the renal microvasculature. The thickness of the medial wall
            of arterioles and small arteries differed significantly among all groups and was increased,
            especially in the small arterial walls of the diabetic rats treated with α-KB. Plasma
            renin activities (PRA) in both diabetic rats treated or untreated with α-KB were decreased
            significantly compared to CNT animals, while diabetic rats treated with α-KB had higher
            angiotensin converting enzyme (ACE) activity than the CNT group (p < 0.01). These
            results suggest that α-KB may have a role in the renal microvascular complications
            of diabetes.
         
         
         
            
Key words
         
         
            α-ketobutyrate (KB) - diabetes mellitus - medial thickness - arteriole - angiotensin
               converting enzyme (ACE) activity
          
      
    
   
      
         References
         
         
            - 1 
               Bradford M M. 
               A rapid and sensitive method for the quantitation of microgram quantities of protein
               utilizing the principle of protein-dye binding. 
               Anal Biochem. 
               1976; 
               72 
               248-254 
               
- 2 
               Elfarra A A, Lash L H, Anders M W. 
               Metabolic activation and detoxication of nephrotoxic cysteine and homocysteine S-conjugates. 
               Proc Natl Acad Sci USA. 
               1986; 
               83 
               2667-2671 
               
- 3 
               Everett A D, Scott J, Wilfong N, Marino B, Rosenkranz R P, Inagami T, Gomez R A. 
               Renin and angiotensinogen expression during the evolution of diabetes. 
               Hypertension. 
               1992; 
               19 
               70-78 
               
- 4 
               Felig P, Marliss E, Ohman J L, Cahill Jr C F. 
               Plasma amino acid levels in diabetic ketoacidosis. 
               Diabetes. 
               1970; 
               19 
               727-728 
               
- 5 
               Higaki J, Ogihara T, Imai N, Kumahara Y, Hontani S, Nishiura M, Ogawa H, Hirose S,
               Murakami K. 
               A new sensitive direct radioimmunoassay for human plasma renin and its clinical application. 
               J Lab Clin Med. 
               1984; 
               104 
               947-954 
               
- 6 
               Hirota R, Nishida S, Takahashi H, Nakagawa S. 
               The influences of insulin and food intake on intestinal ornithine transcarbamylase
               activity in diabetic rats. 
               Exp Clin Endocrinol Diabetes. 
               1998; 
               106 
               117-122 
               
- 7 
               Jacobs R L, House J D, Brosnan M E, Brosnan J T. 
               Effects of streptozotocin-induced diabetes and of insulin treatment on homocysteine
               metabolism in the rat. 
               Diabetes. 
               1998; 
               47 
               1967-1970 
               
- 8 
               Kasahara Y, Ashihara Y. 
               Colorimetry of angiotensin-I converting enzyme activity in serum. 
               Clin Chem. 
               1981; 
               27 
               1922-1925 
               
- 9 
               Maeda S, Kikkawa R, Haneda M, Togawa M, Koya D, Horide N, Kajiwara N, Uzu T, Shigeta Y.
               
               Reduced activity of renal angiotensin-converting enzyme in streptozotocin-induced
               diabetic rats. 
               J Diabet Complications. 
               1981; 
               5 
               225-229 
               
- 10 
               Nakayama T, Izumi Y, Soma M, Kanmatsuse K. 
               Adrenal renin-angiotensin-aldosterone system in streptozotocin-diabetic rats. 
               Horm Metab Res. 
               1998; 
               30 
               12-15 
               
- 11 
               Qureshi G A. 
               High-performance liquid chromatographic methods with fluorescence detection for the
               determination of branched-chain amino acids and their alpha-keto analogues in plasma
               samples of healthy subjects and uraemic patients. 
               J Chromatogr. 
               1987; 
               400 
               91-99 
               
- 12 
               Reddi A S, Nimmagadda V R, Arora R. 
               Effect of antihypertensive therapy on renal artery structure in type 2 diabetic rats
               with hypertension. 
               Hypertension. 
               2001; 
               37 
               1273-1278 
               
- 13 
               Singh B K, Szamosi I, Shaner D. 
               A high-performance liquid chromatography assay for threonine/serine dehydratase. 
               Anal Biochem. 
               1993; 
               208 
               260-263 
               
- 14 
               Singh R, Barden A, Mori T, Beilin L. 
               Advanced glycation end-products: a review. 
               Diabetologia. 
               2001; 
               44 
               129-146 
               
- 15 
               Steele R D. 
               Transaminative metabolism of alpha-amino-n-butyrate in rats. 
               Metabolism. 
               1982; 
               31 
               318-325 
               
- 16 
               Trevisan A, Meneghetti P, Maso S, Troso O. 
               In-vitro mechanisms of 1, 2-dichloropropane nephrotoxicity using the renal cortical
               slice model. 
               Hum Exp Toxicol. 
               1993; 
               12 
               117-121 
               
- 17 
               Yang W, Roth K S. 
               Defect in alpha-ketobutyrate metabolism: a new inborn error. 
               Clin Chim Acta. 
               1985; 
               145 
               173-182 
               
- 18 
               Yeung Y G, Yeung D. 
               Comparative studies on threonine and serine dehydratases in rat liver. 
               Int J Biochem. 
               1980; 
               11 
               161-164 
               
- 19 
               Zoubi S A, Mayhew T M, Sparrow R A. 
               The small intestine in experimental diabetes: cellular adaptation in crypts and villi
               at different longitudinal sites. 
               Virchows Arch. 
               1995; 
               426 
               501-507 
               
Rei Hirota PhD.
            Department of Biochemistry
Nihon University School of Medicine
            
            Itabashi
            
            Tokyo
            
            173-8610, Japan
            
            Telefon: + 81339728111, ex. -2243
            
            Fax: + 81 3 39 72 00 27
            
            eMail: rhirota@med.nihon-u.ac.jp